首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1155篇
  免费   24篇
  国内免费   6篇
耳鼻咽喉   23篇
儿科学   22篇
妇产科学   10篇
基础医学   121篇
口腔科学   8篇
临床医学   100篇
内科学   303篇
皮肤病学   4篇
神经病学   103篇
特种医学   51篇
外科学   231篇
综合类   4篇
预防医学   63篇
眼科学   7篇
药学   51篇
中国医学   8篇
肿瘤学   76篇
  2023年   10篇
  2022年   28篇
  2021年   63篇
  2020年   22篇
  2019年   42篇
  2018年   44篇
  2017年   24篇
  2016年   16篇
  2015年   31篇
  2014年   49篇
  2013年   80篇
  2012年   111篇
  2011年   107篇
  2010年   49篇
  2009年   32篇
  2008年   80篇
  2007年   65篇
  2006年   60篇
  2005年   55篇
  2004年   49篇
  2003年   49篇
  2002年   58篇
  2001年   14篇
  2000年   6篇
  1999年   6篇
  1998年   1篇
  1997年   8篇
  1996年   2篇
  1995年   3篇
  1994年   2篇
  1993年   2篇
  1992年   5篇
  1991年   1篇
  1990年   1篇
  1989年   1篇
  1986年   2篇
  1983年   1篇
  1981年   1篇
  1977年   1篇
  1975年   2篇
  1962年   1篇
  1960年   1篇
排序方式: 共有1185条查询结果,搜索用时 15 毫秒
21.
22.

Objective

To assess the effect of neoadjuvant targeted molecular therapies (TMTs) on size and level of inferior vena cava tumor thrombi and to evaluate their impact on surgical management.

Methods

We retrospectively analyzed the data of 14 patients treated for a clear cell renal cell carcinoma with inferior vena cava thrombi by neoadjuvant TMT before nephrectomy. Clinical, pathological and perioperative data were gathered retrospectively at each institution. The primitive tumor size and the thrombus size were defined by computed tomography before TMT. The tumor thrombus level was defined according to the Novick’s classification.

Results

Before TMT, thrombus level was staged I for 1 (7 %), II for 10 (72 %) and III (21 %) for 3 patients. First-line therapy was sunitinib in 11 cases and sorafenib in 3 cases. Median therapy duration was two cycles (1–5). Three patients experienced major adverse effects (grade III) during TMT. Following TMT, 6 (43 %) patients had a measurable decrease, 6 (43 %) had no change, and 2 (14 %) had an increase in the thrombus. One patient (7 %) had a downstage of thrombus level, 12 (85 %) had stable thrombi, and 1 (7 %) had an upstage. Regarding primary tumor, 7 (50 %), 5 (36 %) and 2 (14 %) patients had a decrease, stabilization and an increase in tumor size, respectively.

Conclusion

Neoadjuvant TMT appears to have limited effects on renal tumor thrombi. This retrospective study failed to demonstrate a significant impact of neoadjuvant TMT on surgical management of clear cell renal cell carcinoma with inferior vena cava tumor thrombi.  相似文献   
23.
24.
ObjectiveTo evaluate the effect of body mass index (BMI) on the outcomes of patients with urinary tract carcinoma treated with radical surgery.Materials and methodsData were collected from 10 Canadian centers on patients who underwent radical cystectomy (RC) (1998–2008) or radical nephroureterectomy (RNU) (1990–2010). Various parameters among subsets of patients (BMI<25, 25≤BMI<30, and BMI≥30 kg/m2) were analyzed. Kaplan-Meier and multivariate analyses were performed to assess the effect of BMI on overall survival, disease-specific survival, and recurrence-free survival (RFS).ResultsAmong the 847 RC and 664 RNU patients, there was no difference in histology, stage, grade, and margin status among the 3 patient subsets undergoing either surgery. However, RC patients with lower BMIs (<25 kg/m2) were significantly older (P = 0.004), had more nodal metastasis (P = 0.03), and trended toward higher stage (P = 0.052). RNU patients with lower BMIs (<25 kg/m2) were significantly older (P = 0.0004) and fewer received adjuvant chemotherapy (P = 0.04) compared with those with BMI≥30 kg/m2; however, there was no difference in tumor location (P = 0.20), stage (P = 0.48), and management of distal ureter among the groups (P = 0.30). On multivariate analysis, BMI was not prognostic for overall survival, disease-specific survival, and RFS in the RC group. However, BMI≥30 kg/m2 was associated with more bladder cancer recurrences and worse RFS in the RNU group (HR = 1.588; 95% CI: 1.148–2.196; P = 0.0052).ConclusionsIncreased BMI did not influence survival among RC patients. BMI≥30 kg/m2 is associated with worse bladder cancer recurrences among RNU patients; whether this is related to difficulty in obtaining adequate bladder cuff in patients with obesity requires further evaluation.  相似文献   
25.
26.
27.
Annals of Hematology - The prognostic significance of hypercalcemia in lymphoma has only been studied on small series to date. We conducted a retrospective, monocentric, matched-control study that...  相似文献   
28.
In this paper we present a general multivariate approach to the analysis of functional imaging studies. This analysis uses standard multivariate techniques to make statistical inferences about activation effects and to describe the important features of these effects. More specifically, the proposed analysis uses multivariate analysis of covariance (ManCova) with Wilk's lambda to test for specific effects of interest (e.g., differences among activation conditions), and canonical variates analysis (CVA) to characterize differential responses in terms of distributed brain systems. The data are subject to ManCova after transformation using their principal components or eigenimages. After significance of the activation effect has been assessed, underlying changes are described in terms of canonical images. Canonical images are like eigenimages but take explicit account of the effects of error or noise. The generality of this approach is assured by the general linear model used in the ManCova. The design and inferences sought are embodied in the design matrix and can, in principle, accommodate most parametric statistical analyses. This multivariate analysis may provide a statistical approach to PET activation studies that 1) complements univariate approaches like statistical parametric mapping, and 2) may facilitate the extension of existing multivariate techniques, like the scaled subprofile model and eigenimage analysis, to include hypothesis testing and statistical inference. © 1996 Wiley-Liss, Inc.  相似文献   
29.
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号